MDGL · CIK 0001157601
What Madrigal Pharmaceuticals, Inc. told the SEC could break it.
Madrigal is a single-product company, and its disclosures concentrate accordingly. Essentially all of its product revenue — about $958.4 million in 2025 — comes from one drug, Rezdiffra, so any safety, competitive, or commercial setback for it threatens the whole business. That revenue funnels through only a limited number of specialty pharmacies that account for substantially all of its U.S. sales, with several individual customers each above 10% of gross product revenue. It also owns no manufacturing facilities and depends entirely on third-party contract manufacturers for both clinical and commercial supply, and as it expands into Europe (a Germany launch in September 2025), it faces country-by-country EU pricing and reimbursement decisions that vary widely.
4 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Customer concentration
- limited specialty pharmacies (substantially all U.S. revenue)high
Madrigal distributes Rezdiffra in the U.S. through only a limited number of specialty pharmacies that account for substantially all of its U.S. revenue; multiple individual customers exceeded 10% of gross product revenue.
“These specialty pharmacies account for substantially all of our revenue in the U.S.”
SEC filing →As of 2026
Other disclosures
- single-product dependence (Rezdiffra)medium
Madrigal's entire product revenue (~$958.4M in 2025) comes from a single drug, Rezdiffra; any safety, competitive (generics) or commercial setback for Rezdiffra would threaten the whole business.
“For the year ended December 31, 2025, we generated $958.4 million in product revenue from sales of Rezdiffra.”
SEC filing →As of 2026
Regulatory & policy
- EU Member-State drug pricing & reimbursementmedium
Madrigal's European commercialization of Rezdiffra (launched in Germany Sept 2025) depends on pricing and reimbursement terms set country-by-country at the EU Member-State level, with widely varying requirements.
“Pricing and reimbursement decisions are made at the Member State level in the EU and the policies, evidentiary requirements, and assessment methodologies governing drug pricing and reimbursement vary widely from country to country.”
Supplier concentration
- third-party contract manufacturers (no in-house manufacturing)medium
Madrigal owns no manufacturing facilities and relies entirely on third-party manufacturers for both clinical and commercial supply of Rezdiffra.
“we currently rely, and expect to rely on third-party manufacturers to supply our product candidates for our clinical trials as well as our commercial supply of Rezdiffra.”
SEC filing →As of 2026
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch